Biochemical parameters of rat blood in the models of chronic heart failure and chronic kidney disease at the administration of nitric oxide donor

In modern veterinary medicine, the simultaneous occurrence of chronic heart failure and chronic kidney disease is often found. However, the cause and effect often exchange places, which creates great difficulties in the animals’ treatment. Chlofusan acts on both systems. It improves cardiac and renal functions by means of providing cardioprotective and nephroprotective effects. Models of chronic heart failure and chronic kidney disease in rats provide important information on the pathophysiology of these diseases in other animal species, and the assessment of changes in the biochemical analysis of blood makes it possible to assess the state of the heart and kidneys in the study. In the course of research, the results of rat biochemical analysis were studied on models of chronic heart and kidney failure with the introduction of an exogenous nitric oxide donor. Chlofuzan contributes to a partial balance restoration of biochemical blood parameters in rats, which indicates the restoration of the mutual work of the heart and kidneys.

Download Full-text

Faculty Opinions recommendation of A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726323261.793520125 ◽

2016 ◽

Author(s):

Luis Ruilope ◽

Enrique Morales

Keyword(s):

Diabetes Mellitus ◽

Heart Failure ◽

Chronic Kidney Disease ◽

Chronic Heart Failure ◽

Kidney Disease ◽

Randomized Controlled Study ◽

Controlled Study ◽

Randomized Controlled

Download Full-text

Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease

European Journal of Heart Failure ◽

10.1002/ejhf.218 ◽

2015 ◽

Vol 17 (2) ◽

pp. 224-232 ◽

Cited By ~ 54

Author(s):

Bertram Pitt ◽

Stefan D. Anker ◽

Michael Böhm ◽

Mihai Gheorghiade ◽

Lars Køber ◽

...

Keyword(s):

Heart Failure ◽

Chronic Kidney Disease ◽

Chronic Heart Failure ◽

Kidney Disease ◽

Receptor Antagonist ◽

Mineralocorticoid Receptor ◽

Randomized Study ◽

Mineralocorticoid Receptor Antagonist

Download Full-text

Abstract 17220: Effects of the Oral Adsorbent of AST-120 in Patients with both Chronic Heart Failure and Chronic Kidney Disease

Circulation ◽

10.1161/circ.130.suppl_2.17220 ◽

2014 ◽

Vol 130 (suppl_2) ◽

Author(s):

Miki Imazu ◽

Masanori Asakura ◽

Takuya Hasegawa ◽

Hiroshi Asanuma ◽

Shin Ito ◽

...

Keyword(s):

Heart Failure ◽

Chronic Kidney Disease ◽

Chronic Heart Failure ◽

Kidney Disease ◽

Diastolic Dysfunction ◽

Uremic Toxins ◽

Control Group ◽

Blood Levels ◽

Uremic Toxin ◽

Oral Adsorbent

Background: One of uremic toxins, indoxyl sulfate (IS) is related to the progression of chronic kidney disease (CKD) and the worse cardiovascular outcomes. We have previously reported the relationship between IS levels and the severity of chronic heart failure (CHF), but the question arises as to whether the treatment of uremic toxin is beneficial in patients with CHF. This study aimed to elucidate whether the treatment with the oral adsorbent which reduces uremic toxin improved the cardiac function of the patients with CHF. Methods: First of all, we retrospectively enrolled 49 patients with both CHF and stage ≤3 CKD in our institute compared with the healthy subjects without CHF or CKD in the resident cohort study of Arita. Secondly, we retrospectively enrolled 16 CHF outpatients with stage 3-5 CKD. They were treated with and without the oral adsorbent of AST-120 for one year termed as the treatment and control groups, respectively. We underwent both blood test and echocardiography before and after the treatment. Results: First of all, among 49 patients in CHF patients, plasma IS levels increased to 1.38 ± 0.84 μg/ml from the value of 0.08 ± 0.06 μg/ml in Arita-cho as a community-living matched with gender and eGFR of CHF patients. We found both fractional shortening (FS) and E/e’, an index of diastolic function were decreased (25.0 ± 12.7%) and increased (13.7 ± 7.5), respectively in CHF patients compared with the value of FS and E/e’ in Arita-cho (FS: 41.8 ± 8.3%, E/e’: 8.8 ± 2.1). Secondly, in the treatment group, the plasma IS levels and the serum creatinine and brain natriuretic peptide levels decreased (1.40 ± 0.17 to 0.92 ± 0.15 μg/ml; p<0.05, 1.91 ± 0.16 to 1.67 ± 0.12 mg/dl; p<0.05, 352 ± 57 to 244 ± 49 pg/ml; p<0.05, respectively) and both FS and E/e’ were improved following the treatment with AST-120 (28.8 ± 2.8 to 32.9 ± 2.6%; p<0.05, 18.0 ± 2.0 to 11.8 ± 1.0; p<0.05). However, these parameters did not change in the control group. Conclusions: The treatment to decrease the blood levels of uremic toxins improved not only renal dysfunction but cardiac systolic and diastolic dysfunction in patients with chronic heart failure. Oral adsorbents might be a new treatment of heart failure especially with diastolic dysfunction.

Download Full-text